Evidence map›Paper›PMID 42182270›Full record

ArticlebioRxiv : the preprint server for biology2026

Small-molecule modulators of HIPK4 activity and proteostasis.

Zaile Zhuang, Riley K Togashi, Patrick Kearney, Ian Pass, Steven M Swick, Fu-Yue Zeng, Andrey A Bobkov, Lynn M Fujimoto, Shubhankar Dutta, Athina Zerva and 10 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Zaile ZhuangDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-3294-5805
Riley K TogashiDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.ORCID 0000-0001-7499-3189
Patrick KearneySanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0009-0004-9848-9947
Ian PassSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0009-0008-5920-0329
Steven M SwickDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.ORCID 0000-0003-3144-0191
Fu-Yue ZengSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0009-0003-7375-1016
Andrey A BobkovSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-9028-3635
Lynn M FujimotoSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-7239-1501
Shubhankar DuttaSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0009-0006-6496-5137
Athina ZervaInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID 0009-0005-5221-9471
Nicolai D RaigInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0002-2075-7938
Debasmita SahaSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0003-0999-0760
Atoosa EmamiSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Martin P SchwalmInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0002-1252-1829
Bradley K MoonDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Samuel T HowardDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Stefan KnappInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0001-5995-6494
Thomas HankeInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0001-7202-9468
Thomas D Y ChungSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0003-4856-6233
James K ChenDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-9220-8436

Funding

Preclinical testing of a novel non-hormonal intravaginal ring to prevent pregnancy and sexually transmitted infectionsP50HD106793 · NICHD · POPULATION COUNCIL · PI HADDAD, LISA BLAKE · 2021 to 2025
$11.1M
Chemical tools for developmental biologyR35GM127030 · NIGMS · STANFORD UNIVERSITY · PI JAMES K CHEN · 2018 to 2026
$6.3M
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptivesR33HD099720 · NICHD · STANFORD UNIVERSITY · PI CHEN, JAMES K, CHUNG, THOMAS D Y · 2021 to 2023
$2.6M
Molecular Pharmacology Training ProgramT32GM136631 · NIGMS · STANFORD UNIVERSITY · PI BOGYO, MATTHEW, CHEN, JAMES K · 2021 to 2025
$2.0M
Refeyn TwoMP Mass Photometer with MassFluidix Microfluidic High Concentration (HC) TechnologyS10OD038355 · OD · STANFORD UNIVERSITY · PI FERNANDEZ FLEISCHHAUER, DANIEL HUGO · 2025 to 2025
$288k
NICHD NIH HHS P50 HD106793NICHD NIH HHS R33 HD099720NIGMS NIH HHS R35 GM127030NIGMS NIH HHS T32 GM136631NIH HHS S10 OD038355
6 · The paper itself

Abstract

Homeodomain-interacting protein kinase 4 (HIPK4) is a dual-specificity kinase that is predominantly expressed in differentiating spermatids, required for sperm development, and a promising target for nonhormonal male contraception. Genetic and functional studies have established an essential role for HIPK4 in spermiogenesis, where it acts at least in part through regulation of the F-actin-scaffolded acroplaxome during spermatid head shaping. The direct molecular targets of HIPK4 and their downstream effectors remain poorly defined, and small-molecule probes would be versatile tools for further investigating HIPK4 functions. Synthetic HIPK4 ligands could also be valuable leads for the development of nonhormonal male contraceptives. Here, we report the discovery of a cyanoquinoline-based series of HIPK4 inhibitors with nanomolar potency. Our lead compounds are selective for HIPK4, both within the HIPK family and across the broader kinome, establishing this scaffold as a useful starting point for probe and lead development. Unexpectedly, we found that a subset of these cyanoquinolines also perturbs HIPK4 proteostasis in a cell type-specific manner. In spermatids, these compounds induce the formation of detergent-insoluble HIPK4 aggregates and promote interactions between this kinase and the autophagy receptor Tax1-binding protein 1 (TAX1BP1). Together, our findings establish cyanoquinoline ligands as a new chemotype for probing HIPK4 biology and advancing male contraceptive discovery.

Identifiers

PMID42182270
PMCPMC13192959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.